Why foreign pharmaceutical companies
need local QPPV support in Nigeria

Why foreign pharmaceutical companies need local QPPV support in Nigeria

For many pharmaceutical manufacturers, entering Nigeria begins with product registration. A dossier is prepared, documents are submitted, regulatory correspondence is managed, and the company works toward market authorization. But registration is not the end of regulatory responsibility. In many ways, it is the beginning of a new phase.

Once a medicine is approved, imported, distributed, prescribed, dispensed, or used by patients, the company’s responsibility expands into post-marketing safety. This is where pharmacovigilance becomes essential. For foreign manufacturers, Marketing Authorization Holders, importers, and distributors, local QPPV support is becoming increasingly important because safety obligations do not stop at the border.

What is a QPPV?

A Qualified Person for Pharmacovigilance, commonly referred to as a QPPV, is responsible for oversight of a company’s pharmacovigilance system. The role helps ensure that safety responsibilities are assigned, documented, and operationalized. In practical terms, the QPPV function supports the organization by ensuring that adverse event reports, safety concerns, signal information, risk documentation, and regulatory safety obligations are managed appropriately.

Why Nigeria requires local pharmacovigilance attention

Nigeria is one of Africa’s most important pharmaceutical markets. It has a large population, an active medicines supply chain, a growing demand for quality healthcare products, and a regulatory environment that increasingly expects companies to demonstrate responsibility beyond product registration. Without a clear local system, safety issues may be missed, delayed, poorly documented, or not escalated properly.

The commercial risk of weak pharmacovigilance

A weak pharmacovigilance system can expose a company to regulatory queries, delayed lifecycle actions, poor distributor oversight, reputational damage, weak response to safety concerns, loss of confidence from partners or regulators, and internal uncertainty about roles and responsibilities. For manufacturers trying to build long-term market presence, this matters. Market access is not only about getting in. It is about staying in.

Why foreign companies need local support

Foreign manufacturers often have strong global systems, but those systems still need local implementation. A global safety department may understand internal reporting requirements, but it may not know the practical realities of Nigerian distribution, local regulatory expectations, local partner behavior, documentation gaps, or communication pathways. Local QPPV support helps create a bridge between global standards and Nigeria’s operational environment. This may include acting as a local pharmacovigilance contact, supporting PV system setup, coordinating adverse event reporting processes, helping align distributors and local partners, supporting safety documentation, assisting with SOP development, and coordinating readiness reviews.

How MedNova supports QPPV and pharmacovigilance readiness

MedNova Lifesciences supports pharmaceutical companies entering and operating in Nigeria by helping them build practical, documented, and locally responsive pharmacovigilance systems. Our services include local QPPV support, pharmacovigilance system development, ICSR coordination support, signal and safety monitoring support, risk management documentation support, distributor and MAH safety oversight support, PV SOP and process support, and integration with regulatory affairs and lifecycle management.

QPPV and regulatory affairs should not be separate conversations

In many companies, pharmacovigilance and regulatory affairs are treated as separate functions. But in real-world market operations, they are closely linked. A safety issue may affect regulatory communication, a variation may require updated safety documentation, and a renewal may require evidence that the company is maintaining appropriate post-marketing responsibilities. That is why MedNova integrates QPPV, pharmacovigilance, regulatory affairs, and clinical development support under one life sciences operating model.

Who should consider local QPPV support?

Local QPPV or PV support may be relevant for foreign pharmaceutical manufacturers entering Nigeria, MAHs with products already registered in Nigeria, importers and distributors managing multiple brands, companies preparing renewals or variations, and companies expanding product portfolios. The earlier this system is built, the better. Waiting until a safety issue arises is usually more expensive, more stressful, and more damaging than preparing properly from the beginning.